复发难治弥漫大B细胞淋巴瘤的二线治疗:自体造血干细胞移植或嵌合抗原受体T细胞治疗?
Second-line treatment of relapsed and refractory diffuse large B-cell lymphoma:autologous stem cell transplantation or chimeric antigen receptor T-cell?
李柠汶 1曹阳 1张义成1
作者信息
- 1. 华中科技大学同济医学院附属同济医院血液内科 湖北武汉,430030
- 折叠
摘要
弥漫性大B细胞淋巴瘤(DLBCL)是最常见的侵袭性淋巴瘤亚型.一线规范的治疗后,60％的患者可以实现治愈,但是仍有40％的患者复发或者难治,预后不佳.挽救性化疗联合自体造血干细胞移植(ASCT)是化疗敏感患者的标准二线治疗方案.然而,伴随着新的治疗方式,如嵌合抗原受体T细胞疗法、双特异性抗体、靶向药物等的出现,标准二线治疗方案受到一定的挑战,尤其对于挽救性化疗不够敏感的患者.本文对目前复发难治DLBCL的二线治疗的安全性和疗效及适应证进行综述,以探讨复发难治DLBCL的最佳治疗选择.
Abstract
Diffuse large B-cell lymphoma(DLBCL)is the most common aggressive subtype of lymphoma.After first-line standard immunochemotherapy,60％of patients can be cured,but there are still 40％of patients with relapse or refrac-tory(R/R),and the prognosis is often poor.Salvage chemotherapy combined with autologous stem cell transplantation is the standard second-line strategy for chemotherapy-sensitive patients.However,with the emergence of new therapeutic modalities,such as CAR-T cell therapy,bispecific antibodies,targeted drugs,standard second-line treatment options have been chal-lenged,especially for patients who are not sensitive to salvage chemotherapy.This article will review the safety,efficacy and indications of current second-line therapies for R/R DLBCL,so as to explore the best treatment options for R/R DLBCL.
关键词
自体造血干细胞移植/嵌合抗原受体T细胞疗法/弥漫性大B细胞淋巴瘤Key words
Autologous hematopoietic stem cell transplantation/Chimeric antigen receptor T cell therapy/Diffuse large B-cell lymphoma引用本文复制引用
出版年
2024
NETL
NSTL
万方数据